Shares of Eli Lilly dropped in pre-market trading Thursday, as competitor Novo Nordisk secured a major win on insurance coverage of its obesity drug and as Lilly reported first-quarter earnings that fell short of what investors wanted to see. CVS Caremark, the largest pharmacy benefit manager in the U.S., announced Thursday that starting in July, … Read more
The risk for ocular problems linked to different formulations of semaglutide appear to vary, according to a new study, which also identified differences based on sex, age, and timing of onset. Medscape Medical News
Can “Ozempic face,” gastrointestinal distress, and nausea be mitigated? This episode features audio from https://nutritionfacts.org/video/how-to-control-the-side-effects-including-ozempic-face-of-glp-1-drugs/ Visit the video page for all sources and doctor’s notes related to this podcast. https://NutritionFacts.org • Subscribe: https://nutritionfacts.org/subscribe • Donate: https://nutritionfacts.org/donate • Podcast : https://nutritionfacts.org/audio • Books: https://nutritionfacts.org/books • Shop: https://drgreger.org • Facebook: https://www.facebook.com/NutritionFacts.org • Twitter: https://twitter.com/nutrition_facts • Instagram: https://www.instagram.com/nutrition_facts_org
CVS to boost access to Novo Nordisk’s weight loss treatment Wegovy for patients on its drug plans CNBC Novo Nordisk announces that CVS Caremark®, the country’s largest PBM, has decided Wegovy® will be the preferred GLP-1 medicine covered for obesity on its template formularies PR Newswire Eli Lilly shares fall as competitor Novo notches coverage win for … Read more
Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are wafting across the Pharmalot campus, where the official mascots are foraging for their breakfast and rousing the neighbors. This means we are free to focus on the matters at hand — rummaging through our to-do list … Read more
Healthify is banking on the rise of GLP-1 weight-loss drugs in India, integrating them with lifestyle coaching. The firm anticipates strong revenue growth, aiming for a 20% increase, while addressing side-effects and weight maintenance post-treatment.